A host of China stocks are recommended by investment analysts whether or not the economy gets a boost from measures taken this week to boost the sluggish domestic economy there. On Tuesday, the People's Bank of China announced a series of steps designed to lift the country's slumping economy.
On Sunday, Morgan Stanley analyst Terence Flynn initiated research coverage of the stock with an overweight rating and $118 price target, implying that shares could soar 168%. "Based on Ph1/2a data, we believe GSBR1290's profile is competitive to that of other oral diabesity drugs on the market and in development . We expect Ph2b obesity data for GSBR-1290 by YE25, representing the next catalyst for the program," Flynn wrote.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: